FocalTherics (NASDAQ:FOCL) Posts Quarterly Earnings Results, Misses Expectations By $0.19 EPS

FocalTherics (NASDAQ:FOCL) posted its quarterly earnings data on Friday. The company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.19), FiscalAI reports. FocalTherics had a negative return on equity of 175.45% and a negative net margin of 56.26%.The business had revenue of $13.20 million during the quarter.

FocalTherics Trading Up 2.8%

FOCL stock traded up $0.13 during trading on Friday, reaching $4.76. 355,833 shares of the stock were exchanged, compared to its average volume of 138,346. FocalTherics has a twelve month low of $1.30 and a twelve month high of $6.40. The company has a debt-to-equity ratio of 1.79, a current ratio of 1.34 and a quick ratio of 0.99. The firm has a market capitalization of $178.40 million, a P/E ratio of -4.62 and a beta of -0.04. The business’s 50 day simple moving average is $5.39.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on FOCL shares. Piper Sandler reaffirmed a “neutral” rating and issued a $4.00 target price on shares of FocalTherics in a report on Friday. Wall Street Zen upgraded FocalTherics to a “hold” rating in a report on Saturday, August 1st. Mizuho set a $15.00 price objective on shares of FocalTherics and gave the stock an “outperform” rating in a research note on Friday, July 17th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of FocalTherics in a research report on Tuesday, June 2nd. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, FocalTherics currently has a consensus rating of “Hold” and a consensus target price of $7.75.

Institutional Trading of FocalTherics

Several institutional investors have recently modified their holdings of FOCL. Rock Springs Capital Management LP increased its position in shares of FocalTherics by 7.1% during the first quarter. Rock Springs Capital Management LP now owns 1,378,000 shares of the company’s stock valued at $5,126,000 after purchasing an additional 91,500 shares during the period. Flax Pond Capital LLC bought a new position in FocalTherics in the fourth quarter worth $2,623,000. Leonteq Securities AG acquired a new stake in FocalTherics during the fourth quarter worth $313,000. Kovack Advisors Inc. bought a new stake in FocalTherics in the 4th quarter valued at $53,000. Finally, Lido Advisors LLC bought a new stake in FocalTherics in the 1st quarter valued at $40,000. Institutional investors and hedge funds own 62.74% of the company’s stock.

About FocalTherics

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.